Anji Biotech has been deeply engaged in innovative peptide drug R&D. Relying on its four self-developed core technology platforms, the company has built a fully integrated peptide drug R&D system covering novel target discovery and endogenous micropeptide identification, precise rational design of targeted peptide molecules, drug conjugation optimization, and systematic druggability evaluation — spanning the entire process from early discovery, molecular optimization and druggability assessment to preclinical validation.
Through its high-throughput novel target and micropeptide discovery platform, the company has established an efficient, high-throughput system for endogenous micropeptide discovery. Leveraging bioinformatics analysis, high-throughput screening systems and differentiated target validation technologies, it precisely identifies and validates novel functional targets and micropeptides, breaking through the industry pain points of single-source targets and molecular homogeneity in traditional peptide drugs, and continuously expanding the boundaries and applications of peptide drug R&D while providing core molecular reserves and target support for source-level innovative drug development.
Building on its structure-targeted peptide computer-aided rational design platform, Anji Biotech integrates years of peptide drug R&D experience to achieve precise and intelligent innovative design of peptide molecules.
Its peptide-conjugated drug platform focuses on precision delivery technologies for peptide drugs, flexibly adapting to R&D needs across different mechanisms of action to develop diversified conjugated peptide molecular structures.
The supporting druggability evaluation platform provides a comprehensive peptide drug druggability assessment system, enabling rapid screening of candidate molecules early in drug development and substantially shortening peptide drug R&D cycles while reducing overall development costs.
The four platforms work in efficient synergy and deep interconnection, forming a closed-loop core capability for innovative peptide drug R&D that combines source-level innovation vitality with industrial translation advantages. Driven by these technology platforms, the company continues to address unmet clinical needs, focus on high-value innovative peptide drugs, and is committed to building an innovative drug pipeline with distinctive differentiation and sustainable iteration.
